{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:58:55Z","timestamp":1790611135488,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03695-0","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:26:20Z","timestamp":1784795180000},"page":"4848-4869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Matching-Adjusted Indirect Comparison of PET-Guided BrECADD Versus PET-Guided ABVD, BEACOPP, and eBEACOPP in Advanced Hodgkin Lymphoma"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4618-876X","authenticated-orcid":false,"given":"Alexa","family":"Molinari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fjoralba","family":"Kristo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Paly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Zomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Stache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijiao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jaworek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hishan","family":"Tharmaseelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoora","family":"Moradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"1","key":"3695_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01281-9","volume":"15","author":"J Huang","year":"2022","unstructured":"Huang J, Pang WS, Lok V, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022;15(1):57. https:\/\/doi.org\/10.1186\/s13045-022-01281-9.","journal-title":"J Hematol Oncol"},{"key":"3695_CR2","volume-title":"StatPearls [Internet]","author":"H Kaseb","year":"2023","unstructured":"Kaseb H, Babiker HM. Hodgkin Lymphoma. In: StatPearls [Internet]. StatPearls Publishing; 2023."},{"issue":"27","key":"3695_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201367.","journal-title":"J Clin Oncol"},{"key":"3695_CR4","unstructured":"German Hodgkin Study Group. Disease Stages and Risk Factors. https:\/\/en.ghsg.org\/disease-stages"},{"key":"3695_CR5","unstructured":"National Cancer Institute Surveillance E, and End Results Program,. Cancer Stat Facts: Hodgkin Lymphoma. Accessed April 16, 2025, https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html"},{"key":"3695_CR6","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hodgkin Lymphoma V.1.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed January 15, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way"},{"issue":"4","key":"3695_CR7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-021-04460-9","volume":"100","author":"J Russell","year":"2021","unstructured":"Russell J, Collins A, Fowler A, et al. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Ann Hematol. 2021;100(4):1049\u201358. https:\/\/doi.org\/10.1007\/s00277-021-04460-9.","journal-title":"Ann Hematol"},{"issue":"9","key":"3695_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/ajh.25871","volume":"95","author":"P Mondello","year":"2020","unstructured":"Mondello P, Musolino C, Dogliotti I, et al. ABVD vs BEACOPP escalated in advanced-stage Hodgkin\u2019s lymphoma: results from a multicenter European study. Am J Hematol. 2020;95(9):1030\u20137. https:\/\/doi.org\/10.1002\/ajh.25871.","journal-title":"Am J Hematol"},{"key":"3695_CR9","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andr\u00e9 M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdy080.","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"3695_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2022-165917","volume":"140","author":"P Borchmann","year":"2022","unstructured":"Borchmann P, Moccia A, Greil R, et al. Treatment related morbidity in patients with classical Hodgkin lymphoma: results of the ongoing, randomized phase III HD21 trial by the German Hodgkin study group. Blood. 2022;140(Supplement 1):771\u20133. https:\/\/doi.org\/10.1182\/blood-2022-165917.","journal-title":"Blood"},{"key":"3695_CR11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210791","author":"German Hodgkin Study Group","year":"2025","unstructured":"German Hodgkin Study Group. Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage hodgkin lymphoma: analysis of the German Hodgkin study group phase III HD18 and HD21 trials. Blood. 2025. https:\/\/doi.org\/10.1182\/blood-2024-210791.","journal-title":"Blood"},{"issue":"17_suppl","key":"3695_CR12","doi-asserted-by":"publisher","first-page":"LBA7000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7000","volume":"42","author":"P Borchmann","year":"2024","unstructured":"Borchmann P, Moccia AA, Greil R, et al. Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study. J Clin Oncol. 2024;42(17_suppl):LBA7000\u2013LBA7000. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA7000.","journal-title":"J Clin Oncol"},{"issue":"10450","key":"3695_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0140-6736(24)01315-1","volume":"404","author":"P Borchmann","year":"2024","unstructured":"Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024;404(10450):341\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(24)01315-1.","journal-title":"Lancet"},{"issue":"27","key":"3695_CR14","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/jco-25-00439","volume":"43","author":"J Ferdinandus","year":"2025","unstructured":"Ferdinandus J, Kaul H, Foss\u00e5 A, et al. Positron emission tomography-guided brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone in older patients with advanced-stage classic Hodgkin lymphoma: a prospective, multicenter, single-arm, phase II cohort of the German Hodgkin study group HD21 trial. J Clin Oncol. 2025;43(27):2974\u201385. https:\/\/doi.org\/10.1200\/jco-25-00439.","journal-title":"J Clin Oncol"},{"issue":"17","key":"3695_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/jco.2015.63.1119","volume":"34","author":"OW Press","year":"2016","unstructured":"Press OW, Li H, Sch\u00f6der H, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol. 2016;34(17):2020\u20137. https:\/\/doi.org\/10.1200\/jco.2015.63.1119.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3695_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1182\/blood.2019000719","volume":"134","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Li H, Sch\u00f6der H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma. Blood. 2019;134(15):1238\u201346. https:\/\/doi.org\/10.1182\/blood.2019000719.","journal-title":"Blood"},{"issue":"25","key":"3695_CR17","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374(25):2419\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1510093.","journal-title":"N Engl J Med"},{"key":"3695_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01177","author":"S Luminari","year":"2023","unstructured":"Luminari S, Fossa A, Trotman J, et al. Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.23.01177.","journal-title":"J Clin Oncol"},{"issue":"24","key":"3695_CR19","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa022473","volume":"348","author":"V Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease. N Engl J Med. 2003;348(24):2386\u201395. https:\/\/doi.org\/10.1056\/NEJMoa022473.","journal-title":"N Engl J Med"},{"issue":"10","key":"3695_CR20","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/s2352-3026(18)30140-6","volume":"5","author":"B von Tresckow","year":"2018","unstructured":"von Tresckow B, Kreissl S, Goergen H, et al. Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018;5(10):e462\u201373. https:\/\/doi.org\/10.1016\/s2352-3026(18)30140-6.","journal-title":"Lancet Haematol."},{"issue":"1","key":"3695_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdi023","volume":"16","author":"V Ballova","year":"2005","unstructured":"Ballova V, R\u00fcffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16(1):124\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdi023.","journal-title":"Ann Oncol."},{"key":"3695_CR22","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016"},{"key":"3695_CR23","unstructured":"Mitchell M, Muftakhidinov B, Winchen T. Engauge Digitizer Software. http:\/\/markummitchell.github.io\/engauge-digitizer"},{"key":"3695_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"3695_CR25","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics. 2010. https:\/\/doi.org\/10.2165\/11538370-000000000-00000.","journal-title":"PharmacoEconomics"},{"key":"3695_CR26","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s40273-015-0271-1","volume":"21","author":"KJ Ishak","year":"2015","unstructured":"Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. PharmacoEconomics. 2015;21:2015. https:\/\/doi.org\/10.1007\/s40273-015-0271-1.","journal-title":"PharmacoEconomics"},{"issue":"2","key":"3695_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989x17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311. https:\/\/doi.org\/10.1177\/0272989x17725740.","journal-title":"Med Decis Making"},{"issue":"3","key":"3695_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/s0266462319000333","volume":"35","author":"DM Phillippo","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of national institute for health and care excellence technology appraisals. Int J Technol Assess Health Care. 2019;35(3):221\u20138. https:\/\/doi.org\/10.1017\/s0266462319000333.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"3695_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12891-021-04379-2","volume":"22","author":"I Kuitunen","year":"2021","unstructured":"Kuitunen I, Ponkilainen VT, Uimonen MM, Eskelinen A, Reito A. Testing the proportional hazards assumption in cox regression and dealing with possible non-proportionality in total joint arthroplasty research: methodological perspectives and review. BMC Musculoskelet Disord. 2021;22(1):489. https:\/\/doi.org\/10.1186\/s12891-021-04379-2.","journal-title":"BMC Musculoskelet Disord"},{"key":"3695_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152. https:\/\/doi.org\/10.1186\/1471-2288-13-152.","journal-title":"BMC Med Res Methodol"},{"key":"3695_CR31","doi-asserted-by":"crossref","unstructured":"Jiang Z, Liu J, He W, et al. The hazards of using hazard ratios from proportional hazard models in indirect treatment comparisons. Research Synthesis Methods. 2025:1-15.","DOI":"10.1017\/rsm.2025.10059"},{"key":"3695_CR32","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/. 2022"},{"key":"3695_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2609296","author":"F Kristo","year":"2026","unstructured":"Kristo F, Molinari A, Lan Z, et al. Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma. Future Oncol. 2026. https:\/\/doi.org\/10.1080\/14796694.2025.2609296.","journal-title":"Future Oncol"},{"issue":"10","key":"3695_CR34","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","volume":"14","author":"N Skoetz","year":"2013","unstructured":"Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943\u201352.","journal-title":"Lancet Oncol"},{"key":"3695_CR35","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S179356","author":"T Zhang","year":"2018","unstructured":"Zhang T, Yao Y, Feng F, et al. Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis. Cancer Manag Res. 2018. https:\/\/doi.org\/10.2147\/CMAR.S179356.","journal-title":"Cancer Manag Res"},{"issue":"Supplement 1","key":"3695_CR36","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/blood-2025-3618","volume":"146","author":"T Porges","year":"2025","unstructured":"Porges T, Levi T, Dann E, Aumann S, Gurion R, Buchrits S, et al. Real world experience with brecadd protocol as frontline therapy for patients with advanced stage classical Hodgkin lymphoma: a multicenter retrospective study. Blood. 2025;146(Supplement 1):3618. https:\/\/doi.org\/10.1182\/blood-2025-3618.","journal-title":"Blood"},{"key":"3695_CR37","doi-asserted-by":"publisher","first-page":"101088","DOI":"10.1016\/j.vhri.2025.101088","volume":"47","author":"CM Farinasso","year":"2025","unstructured":"Farinasso CM, Ferreira VL, Medeiros FC, et al. Matching-adjusted indirect comparison studies in oncology: a scoping review focused on reporting quality. Value Health Reg Issues. 2025;47:101088.","journal-title":"Value Health Reg Issues"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03695-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:22Z","timestamp":1790609962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03695-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3695"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03695-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fjoralba Kristo, Alexa Molinari, Victoria Paly, Athanasios Zomas, and Vanessa Stache report employment and ownership of stock\/shares with Takeda. Zhiyi Lan, Zijiao Yuan, Abbey Poirier, and Hoora Moradian were employed by Cytel Inc., at the time of this study, which received consulting fees from Takeda associated with the study and manuscript. Christian Jaworek and Hishan Tharmaseelan report employment by the Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany. Thomas Melchardt reports employment by Paracelsus Medical University, Salzburg, Austria.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article reports a retrospective analysis using individual patient data from the HD21 trial and aggregate data extracted from published studies (SWOG S0816, RATHL, HD9, and Mondello 2020 [\n                      \n                      ]). Review boards at participating institutions had previously approved all procedures for the HD21, SWOG S0816, RATHL, and HD9 trials. As the present study is a retrospective analysis of existing trial and published data and did not involve new patient recruitment or intervention, no additional institutional review board review was required for this analysis.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}